TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03620032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)

Intervention type: DRUG
Group type: OTHER
Intervention: Nimotuzumab
Description: humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine
Description: Chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS

Intervention type: OTHER
Group type: OTHER
Intervention: Radiotherapy
Description: RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
Study: NCT02944838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Senior Change Makers Advocacy Program
Description: see description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Senior Change Makers Physical Activity Program
Description: see description
Study: NCT03696550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline (TP-434)
Description: Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline (TP-434)
Description: Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)
Study: NCT00200707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous bone marrow mononuclear cells
Study: NCT02866162

Intervention type: GENETIC
Intervention: High-throughput exome sequencing
Study: NCT03474263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biologic: IC14 (monoclonal antibody against human CD14)
Description: IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
Study: NCT00023712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01985971

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Study: NCT00587444

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: 300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is\>480 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HH or high heparin
Description: initial dose of 450u/kg for CPB ACT performed additional bolus given if result is \<600 seconds anytime during CPB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin concentration HC
Description: will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%
Study: NCT00582699

Intervention type: BEHAVIORAL
Intervention: assessment interview and blood draw
Description: All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.

Intervention type: BEHAVIORAL
Intervention: assessment interview and blood draw
Description: All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
Study: NCT01047007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib 20 mg
Description: Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib 20 mg
Description: Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib 20 mg
Description: Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU 1000 mg/m^2/day
Description: 5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU 1000 mg/m^2/day
Description: 5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU 1000 mg/m^2/day
Description: 5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Description: CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib 65 mg
Description: Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib 65 mg
Description: Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
Study: NCT04833868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy and schroth exercise
Description: pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: schroth exercise
Description: pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
Study: NCT02155101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART with 2 NRTIs plus LPV/r (or ATV/r)
Description: Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
Study: NCT02060929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
Study: NCT04649216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371
Description: PCO371 Capsule
Study: NCT00958516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 cream
Description: LEO 29102 cream in different doses and the cream vehicle
Study: NCT00742846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine + Kenalog
Description: 5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid
Study: NCT04649216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PCO371
Description: \[14C\]PCO371 Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PCO371
Description: \[14C\]PCO371 Solution for infusion
Study: NCT01424358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Educational Intervention
Description: The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
Study: NCT03610854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness Tracker
Description: Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
Study: NCT02185261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
Study: NCT04470882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with faded safety behaviors
Description: Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure without safety behaviors
Description: Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with unfaded safety behaviors
Description: Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
Study: NCT02433496

Intervention type: OTHER
Intervention: Physician coaching
Description: The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice.
Study: NCT00742846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine + Kenalog
Description: 5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space
Study: NCT03819387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBF-006
Description: Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
Study: NCT01597648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivir
Description: 1 tablet: lamivudine 150mg, zidovudine 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivir
Description: 1 tablet: lamivudine 150mg, zidovudine 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838510
Description: Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
Study: NCT02955888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI4050
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study: NCT03886948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered subcutaneously (SC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe (PFS)
Description: PFS used to administer LY3074828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Description: AI used to administer LY3074828
Study: NCT01732705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
Study: NCT00291031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Description: Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments.
Study: NCT01456793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Options to Prevent Pregnancy (T.O.P.P.)
Description: Telephone-based care coordination and mobile contraceptive services
Study: NCT02377843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory
Description: The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Efficient
Description: The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice
Study: NCT01986894

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Single oral dose of 4 mg pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Single oral dose of 20 mg pomalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose of 400 mg moxifloxacin tablet
Study: NCT02895178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength exercise training
Description: Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Combined aerobic and strength exercise training
Description: Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
Study: NCT02942888

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide riboside
Description: Oral administration of Niagen ramp up 250mg to 1g/day as tolerated

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Oral administration of Niagen ramp up 250mg to 1g/day as tolerated

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: This is a placebo compounded by ChromaDex, Inc.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar Pill
Description: This is a placebo compounded by ChromaDex, Inc.
Study: NCT03614598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of LMA-UNIQUE(TM) device
Description: LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of LMA-SUPREME(TM) device
Description: LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of I-GEL(R) device
Description: I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
Study: NCT03033680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study: NCT02678962

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SN6AD1
Description: Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SBL-3
Description: Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LS-313 MF30
Description: Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LISA tri 839 MP
Description: Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Bilateral cataract surgery with implantation of ART toric multifocal IOLs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LS-313 MF30T
Description: Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
Study: NCT03882437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-A501
Description: RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
Study: NCT00988156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eslicarbazepine acetate
Description: Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
Study: NCT00742846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection
Study: NCT03810547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 Mg/mL Intravenous Emulsion
Description: when spinal anesthesia is not satisfactory intervention drugs are used
Study: NCT03774771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Capsule for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration